Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $107M (up 44.2% year over year) with net income of $11M.
Q3 2026 key financials · XBRL
- Revenue
- $107M
- +44.2% YoY · +16.4% QoQ
- Net income
- $11M
- +1718.0% YoY · +136.3% QoQ
- Operating margin
- 15.8%
- EPS (diluted)
- $0.07
- +138.9% QoQ
Source: XBRL data from the Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 10-Q on SEC EDGAR. USD.
Xeris Biopharma Holdings, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $107.2M, up 44.2% YoY from $74.4M
- Operating margin 15.8% vs 9.0% YoY, net income $11.3M vs $0.6M
- Best performer Recorlev: $71.5M, up 93.5%; weakest Gvoke: $21.7M, down 13.7%
- Operating cash flow $53.6M vs $8.6M; financing cash outflow $32.9M, including $23.1M debt settlement
- Cash resources sufficient for at least twelve months, with potential future financing needs and ongoing net losses ahead
Risk Factors
- No material changes to risk factors since the December 31, 2025 Form 10-K
- Carried-forward business risks could materially affect operations and consolidated financial statements
- Carried-forward risks could adversely affect results of operations and cash flows
- Unknown or currently immaterial risks could impair business operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xeris Biopharma Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.